Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) (CROSBI ID 326036)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Hayden, PJ ; Roddie, C ; Bader, P ; Basak, GW ; Bonig, H ; Bonini, C ; Chabannon, C ; Ciceri, F ; Corbacioglu, S ; Ellard, R et al. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haemat // Annals of oncology, 33 (2022), 259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16.

Podaci o odgovornosti

Hayden, PJ ; Roddie, C ; Bader, P ; Basak, GW ; Bonig, H ; Bonini, C ; Chabannon, C ; Ciceri, F ; Corbacioglu, S ; Ellard, R ; Sanchez-Guijo, F ; Jäger, U ; Hildebrandt, M ; Hudecek, M ; Kersten, MJ ; Köhl, U ; Kuball, J ; Mielke, S ; Mohty, M ; Murray, J ; Nagler, A ; Rees, J ; Rioufol, C ; Saccardi, R ; Snowden, JA ; Styczynski, J ; Subklewe, M ; Thieblemont, C ; Topp, M ; Ispizua, ÁU ; Chen, D ; Vrhovac, Radovan ; Gribben, JG ; Kröger, N ; Einsele, H ; Yakoub-Agha, I

engleski

Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. Design: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. Results: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post- authorisation safety surveillance and regulatory issues. Conclusions: We provide practical, clinically relevant recommendations on the use of these high- cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic. Keywords: B-cell acute lymphoblastic leukemia (B ALL) ; CAR T-cells ; cytokine release syndrome (CRS) ; immune effector cell associated neurotoxicity syndrome (ICANS) ; large B-cell lymphoma (LBCL) ; multiple myeloma (MM).

CAR T-cell therapy ; best practice recommendations

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

33

2022.

259-275

objavljeno

0923-7534

1569-8041

10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16.

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost